Lung cancer is not the same as death: how can modern treatment change fate?

In the past, the diagnosis of lung cancer almost implied death sentences. However, with the development of medical technology, modern treatment has significantly increased the rate of lung cancer. This paper will describe the current progress in the treatment of lung cancer, including new technologies such as target-based treatment and immunotherapy, and will show us that lung cancer is no longer an “elimination”.Traditionally, lung cancer has been considered to be extremely difficult to cure, but the rate of lung cancer has increased significantly as medicine continues to improve, especially with regard to target and immunization treatment. These new treatments reduce the harm to healthy cells through the precise targeting of cancer cells, which effectively improves the quality of treatment and survival of patients. It is hoped that, through the Copa, lung cancer will be made more aware that lung cancer is not an incurable disease and that early diagnosis and active treatment will continue to provide better planning.Target therapy is the specific molecular target through which drugs directly affect cancer cells, thus inhibiting their growth and spread. Target-oriented treatment has higher selective and lower side effects than traditional chemotherapy. For example, the use of EGFR carcinogenic accelerants (TKIs) can significantly prolong the patient ‘ s lack of progress for patients with lung cancer that mutates the skin growth factor (EGFR). In addition, the ALK inhibitor has shown good therapeutic efficacy for patients who have been recast by the ALK gene.Immunotherapy is used to combat cancer by activation or enhancement of the human own immune system. Immunosuppressants, such as PD-1/PD-L1 inhibitors and CTLA-4 inhibitors, remove cancer cells from the immune system and enable them to identify and attack cancer cells. This treatment has had a breakthrough effect among some patients with lung cancer, especially those with high PD-L1 expression levels.In addition to targeted and immunotherapy, the treatment of lung cancer includes traditional methods such as surgery, treatment and chemotherapy. Out of early lung cancer patients, surgical tumour removal remains the most effective treatment. Treatment can be used for local late lung cancer treatment or combined with surgery. While the side effects of chemotherapy are significant, in some cases, such as late lung cancer or transmissible lung cancer, they remain important treatments.The treatment of lung cancer is becoming more and more individualized as precision medicine continues to develop. Through in-depth analysis of the genetic and molecular characteristics of patients ‘ tumours, doctors can tailor more precise treatments to each patient. For example, the emergence of liquid detection techniques allows doctors to detect tumour genetic information in the patient ‘ s blood, thus providing more accurate guidance for treatment decisions.This precision not only increases the relevance of treatment, but also significantly reduces unnecessary side effects. The survival and quality of life of lung cancer patients has improved significantly through a combination of targeted, immunotherapy, surgery, treatment and chemotherapy. Target-oriented treatments can attack specific genes or proteins on tumour cells, while immunotherapy is used to counter cancer cells by activation or enhancement of the patient ‘ s immune system.In the future, as more new drugs and technologies emerge, we have every reason to believe that lung cancer will gradually shift from an “elimination” to a chronic disease that can be effectively controlled. This means not only that patients will have a longer life span, but also that they will be able to enjoy a better quality of life in treatment. The development of precision medical care offers new hope for lung cancer patients and new challenges and opportunities for the medical community.